Antiparkinsonian Agent Piribedil Displays Antagonist Properties at ...

Hill MP and Brotchie J (1999) The adrenergic receptor agonist, clonidine, potentiates
the anti-parkinsonian action of the selective �-opioid receptor agonist, enadoline,
in the monoamine-depleted rat. Br J Pharmacol 128:1577–1585.
Hornykiewicz O and Kish SJ (1986) Biochemical pathophysiology in Parkinson’s
disease. Adv Neurol 45:19–34.
Hurtig HI (1997) Problems with current pharmacologic treatment of Parkinson’s
disease. Exp Neurol 144:10–16.
Jackson VN, Bahia DS and Milligan G (1999) Modulation of the relative intrinsic
activity of agonists at the � 2A-adrenoceptor by mutation of residue 351 of G
protein i1�. Mol Pharmacol 55:195–201.
Jäkälä P, Riekkinen M, Sirviö J, Koivisto M and Riekkinin P (1999) Clonidine, but
not guanfacine, impairs choice reaction time performance in young healthy volunteers.
Neuropsychopharmacology 21:495–502.
Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SAO, Daunt DA,
Bonhaus DW and Eglen RM (1998) Ligand efficacy and potency at recombinant � 2
adrenergic receptors agonist-mediated [ 35 S]GTP�S binding. Biochem Pharmacol
55:1035–1043.
Jenner P (1995) The rationale for the use of dopamine agonists in Parkinson’s
disease. Neurology 45:S6–S12.
Kable JW, Murrin LC and Bylund DB (2000) In vivo gene modification elucidates
subtype-specific functions of � 2-adrenergic receptors. J Pharmacol Exp Ther 293:
1–7.
Kribben A. Herget-Rosenthal S, Lange B, Erdbrügger W, Philipp T and Michel MC
(1997) � 2-Adrenoceptors in opossum kidney cells couple to stimulation of mitogenactivated
protein kinase independently of adenylyl cyclase inhibition. Naunyn-
Schmiedeberg’s Arch Pharmacol 356:225–232.
Mavridis M, Colpaert FC and Millan MJ (1991a) Differential modulation of (�)amphetamine-induced
rotation in unilateral substantia nigra-lesioned rats by � 1
as compared to � 2 agonists and antagonists. Brain Res 562:216–224.
Mavridis M, Degryse AD, Lategan AJ, Marien M and Colpaert FC (1991b) Effects of
locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia
nigra cell loss after O-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys. A
possible role for the locus coeruleus in the progression of Parkinson’s disease.
Neuroscience 41:507–523.
Meltzer LT, Wiley JN and Heffner TG (1989) The � 2-adrenoceptor antagonists
idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of
B-HT 920. Eur J Pharmacol 170:105–107.
Millan MJ, Bervoets K, Rivet JM, Widdowson P, Renouard A, Le Marouille-Girardon
S and Gobert A (1994) Multiple � 2-adrenergic receptor subtypes. II. Evidence for
a role of rat R� 2A-ARs in the control of nociception, motor behaviour and hippocampal
synthesis of noradrenaline. J Pharmacol Exp Ther 270:958–972.
Millan MJ, Lejeune F and Gobert A (2000a) Reciprocal autoreceptor and heteroreceptor
control of serotonergic, dopaminergic and noradrenergic transmission in the
frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol
14:114–138.
Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM,
Cordi A and Dekeyne A (2000b) S18616, a highly potent, spiroimidazoline agonist
at � 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function,
and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp
Ther 295:1206–1222.
Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas J-P, Cogé
F, Galizzi J-P, Boutin JA, Rivet JM, et al. (2000c) Agonist and antagonist actions
of yohimbine as compared to fluparoxan at � 2-adrenergic receptors (AR)s, serotonin
(5-HT) 1A, 5-HT 1B, 5-HT 1D and dopamine D 2 and D 3 receptors. Significance for
the modulation of frontocortical monoaminergic transmission and depressive
states. Synapse 35:79–95.
� 2-Adrenoceptors and Parkinson’s Disease 887
Montastruc JL, Rascol O and Senard JM (1996) New directions in the drug treatment
of Parkinson’s disease. Drugs Aging 9:169–184.
Murrin LC, Gerety ME, Happe HK and Bylund DB (2000) Inverse agonism at
� 2-adrenoceptors in native tissue. Eur J Pharmacol 398:185–191.
Newman-Tancredi A, Chaput C, Touzard M and Millan MJ (2000) [ 35 S]-GTP�S
autoradiography reveals � 2-adrenoceptor mediated G-protein activation in amygdala
and lateral septum. Neuropharmacology 39:1111–1113.
Newman-Tancredi A, Nicolas JP, Audinot V, Gavaudan S, Verrièle L, Touzard M,
Chaput C, Richard N and Millan MJ (1998) Actions of � 2-adrenoceptor ligands at
� 2A and 5-HT 1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine,
are highly selective for � 2A adrenoceptors. Naunyn-Schmiedeberg’s
Arch Pharmacol 358:197–206.
Nicholas AP, Hökfelt T and Pieribone VA (1997) The distribution and significance of
CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci
18:210–211.
Pauwels PJ, Tardif S, Wurch T and Colpaert FC (2000) Facilitation of constitutive
� 2-adrenoceptor activity by both single amino acid mutation (thr 373 lys) and G �0
protein coexpression: evidence for inverse agonism. J Pharmacol Exp Ther 292:
654–663.
Peyro-Saint-Paul H, Durif F, Pollak P, Bonnet AM, Payen I, Vidailhet M, Piétan Y
and Agid Y (1997) Short term oral administration of idazoxan in mild stable
parkinsonian patients treated with L-dihydroxyphenylalanine. J Pharmacol Clin
Ther 1:172.
Rascol O, Arnulf I and Agid Y (1997) L-dihydroxyphenylalanine-induced dyskinesias
improvement by an alpha 2-antagonist, idazoxan in patients with Parkinson’s
disease. Mov Disord 12:111.
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE and Lang AE (2000) A
five-year study of the incidence of dyskinesia in patients with early Parkinson’s
disease who were treated with ropirinole or levodopa. N Engl J Med 18:1484–
1491.
Renouard A, Widdowson PS and Millan MJ (1994) Multiple � 2-adrenergic receptor
subtypes. I. Comparison of [ 3 H]RX821002-labelled rat R� 2A-adrenergic receptors
in cerebral cortex to human h� 2A-adrenergic receptors and other populations of
� 2-adrenergic subtypes. J Pharmacol Exp Ther 270:946–957.
Rondot P and Ziegler M (1992) Activity and acceptability of trivastal in Parkinson’s
disease: a multicenter study. J Neurol 239:528–534.
Ruzicka E, Ladure P, Roth J, Jech R, Mecir P and Peyro-Saint-Paul H (1997) Efficacy
and safety of efaroxan, an � 2-adrenoceptor antagonist, in Parkinson’s disease. An
oral short-term study. XIIth International Symposium on Parkinson’s Disease,
March 23–26, London: Abstract 463.
Sandyk R and Iacono RP (1990) Early versus late-onset Parkinson’s disease: the role
of the locus coeruleus. Int J Neurosci 52:243–247.
Seyfried CA and Boettcher H (1990) Central D 2-autoreceptor agonists, with special
reference to indolylbutylamines. Drugs Future 35:819–832.
Sian J, Gerlach M, Youdim MBH and Riederer P (1999) Parkinson’s disease: a major
hypokinetic basal ganglia disorder. J Neural Transm 106:443–476.
Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RKB and Jenner P
(2000) Transdermal administration of piribedil reverses MPTP-induced motor
deficits in the common marmoset. Clin Neuropharmacol 23:133–142.
Trendelenburg AU, Hein L, Gaiser EG and Starke K (1999) Occurrence, pharmacology
and function of presynaptic � 2-autoreceptors in � 2A/D-adrenoceptor-deficient
mice. Naunyn-Schmiedeberg’s Arch Pharmacol 360:540–551.
Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier,
Center de Recherches de Croissy, 125 chemin de Ronde, 78290 Croissy/
Seine, Paris, France. E-mail: mark.millan@fr.netgrs.com
Downloaded from
jpet.aspetjournals.org by guest on February 13, 2013